Renata PLC has completed the shipment of its first consignment of Rosuvastatin, a drug widely used to prevent cardiovascular diseases, to the United States market. 

According to a company statement, the medication was manufactured at Renata’s Bangladesh facility, which has been approved by the US Food and Drug Administration (FDA). This regulatory approval underscores the factory’s adherence to international quality standards for pharmaceutical production.

The drug, marketed under Rolip in Bangladesh, will be introduced in the US market as a bioequivalent and interchangeable formulation to the original innovator product. Renata highlighted that Rosuvastatin provides American patients with a high-quality, cost-effective alternative for cholesterol management, offering identical therapeutic efficacy and safety.

Rolip is available in tablet form with dosage strengths of 5 mg, 10 mg, 20 mg, and 40 mg, ensuring a comprehensive range of treatment options for patients with varying cholesterol management needs.

Renata is supplying an initial 80 lakh units of the medication across all dosage strengths as part of its product launch strategy. The company stated that this effort aims to meet the growing demand for cholesterol management solutions in the US, a market where cardiovascular diseases remain a leading health concern.